cyclosporine ophthalmic emulsion / Generic mfg. - LARVOL DELTA

Topical Cenegermin-Bkbj Dramatically Resolves Neurotrophic Keratitis Associated With Pars Plana Vitrectomy. (PubMed, Ophthalmic Surg Lasers Imaging Retina) - "A 60-year-old woman with recurrent retinal detachments in the right eye after receiving the third PPV developed persistent irritation, photophobia, and worsening visual acuity due to iatrogenic NK despite lubrication, bandage contact lens, preservative-free artificial tears, restasis, and right lower lid punctal cautery over 6 weeks. This case highlights the importance of early recognition, tailored management, and the potential efficacy of Cenegermin-Bkbj in treating NK arising after retinal procedures. [Ophthalmic Surg Lasers Imaging Retina 2025;56:XX-XX.]."

Journal • Keratitis • Ocular Inflammation • Ophthalmology • Retinal Disorders

Drugs for dry eye disease. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Dry Eye Disease • Ophthalmology

Hyaluronic acid conjugates with controlled oleic acid substitution as new nanomaterials for improving ocular co-delivery of cyclosporine A and oleic acid. (PubMed, Asian J Pharm Sci) - "CsA-loaded HONs exhibited improved solution transparency via solubilizing capacity of HON, and increased in vitro drug permeation compared to Restasis®. Interestingly, this CsA-loaded HON1 as optimal ocular nanoformulation showed markedly augmented macrophage polarization into the M2 phenotype, downregulated the expression of proinflammatory cytokines levels in LPS-induced M1 macrophage, and effectively inhibited VEGF-induced endothelial cell proliferation and capillary-like tube formation by the synergistic effect of CsA and HON1 containing OA at the same time. Collectively, the current fatty acid conjugated to HA, named fattigation platform, providing the roles and physicochemical properties via structural features of HA could be a promising co-delivery strategy of drug and fatty acid for DED and other ophthalmic disease treatments."

Journal • Dry Eye Disease • Ocular Inflammation • Ophthalmology

Efficacy and Safety of Topical Cyclosporine 0.05% and Lifitgrast on the Ocular Surface Symptom After Photorefractive Keratectomy in Feiz Hospital, Isfahan, 2024 (clinicaltrials.gov) - P1 | N=150 | Not yet recruiting | Sponsor: Mohsen Pourazizi

New P1 trial • Inflammation • Ocular Inflammation • Pain

Quintessence of currently approved and upcoming treatments for dry eye disease. (PubMed, Graefes Arch Clin Exp Ophthalmol) - "Currently, the US Food and Drug Administration (FDA)-approved medical treatments for treatment of DED include cyclosporine formulations (RESTASIS® [cyclosporine 0.05% ophthalmic emulsion], VEVYE® [cyclosporine 0.1% ophthalmic solution], and CEQUA™ [cyclosporine 0.09% ophthalmic solution]), XIIDRA® (lifitegrast), a leukocyte function-associated antigen-1 (LFA-1)/intracellular adhesion molecule-1(ICAM-1) inhibitor, EYSUVIS™ (loteprednol etabonate ophthalmic suspension 0.25%), a corticosteroid, and MIEBO™ (perfluorohexyloctane ophthalmic solution), a semifluorinated alkane. TYRVAYA™ (varenicline solution nasal spray), a cholinergic agonist, is another formulation approved for the treatment of the signs and symptoms of DED...Cyclosporine formulations TJO-087 (cyclosporine A nanoemulsion 0.08%), SCAI-001 eye drops (cyclosporine 0.01%, 0.02%) are being evaluated against RESTASIS® and other approved treatments. The potential treatments being assessed include..."

Journal • Review • Conjunctivitis • Dry Eye Disease • Ocular Infections • Ocular Inflammation • Ophthalmology • Sjogren's Syndrome • ICAM1

Could Bilateral Progressive Corneal Ectasia Be Transient? Exploring A Case Of Full Reversibility (ESCRS 2024) - "Preservative- free tear substitute and 0.1% cyclosporine ophthalmic emulsion quid were prescribed...Proper recognition of the VKC complications is crucial, as most of these can be managed or prevented. Despite the accuracy of diagnostic tools in diagnosing KC, they cannot replace an accurate clinical examination."

Clinical • Achromatopsia • Astigmatism • Conjunctivitis • Dry Eye Disease • Ocular Infections • Ocular Inflammation • Ophthalmology

Improvement In Total Corneal Staining And Visual Acuity With Cyclosporine Ophthalmic Solution 0.09% In A Phase 4 Study Of Patients With Dry Eye Disease Inadequately Controlled By Cyclosporine Ophthalmic Emulsion 0.05% (ESCRS 2024) - "Twice-daily CsA 0.09% was associated with significant improvements in both total CFS score and BCVA OU at Week 12 of treatment. Additionally, significant reductions in total CFS score in both the right and left eyes were noted at Week 12 regardless of relative BCVA. CsA 0.09% was generally well tolerated throughout the study."

Clinical • P4 data • Dry Eye Disease • Ocular Inflammation • Ophthalmology

Improved Signs and Symptoms of Dry Eye Disease for Restasis® Patients Following a Single Tearcare® Treatment: Phase 2 of the SAHARA Study. (PubMed, Clin Ophthalmol) - "SAHARA showed 6-month superiority of LHT to CsA in clinical signs and non-inferiority in symptom scores. This extension shows that patients treated with CsA for 6 months can achieve meaningful additional improvement in signs and symptoms lasting for as long as 6 months following a single LHT treatment without the need for topical prescription therapy."

Clinical • P2 data • Dry Eye Disease • Ophthalmology

HU007 in Patients With Dry Eye Syndrome (clinicaltrials.gov) - P3 | N=328 | Completed | Sponsor: Huons Co., Ltd. | Recruiting ➔ Completed

Head-to-Head • Trial completion • Dry Eye Disease • Ophthalmology

P2X4 receptor antagonist ameliorate neuropathic ocular pain in a rat lacrimal glands removal model (ARVO 2024) - "Two weeks after the surgery (post-surgery), we divided the animals into three groups: vehicle, 0.05% cyclosporine ophthalmic emulsion, and Bay293 in vehicle at 2.5mg/ml... P2X4 antagonist Bay293 decreased the discomfort perception and enhanced eye comfort, offering a valuable alternative to chronic ocular discomfort management alongside cyclosporine."

Preclinical • Dry Eye Disease • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology • Optic Neuritis • P2RX4

Effect of Topical Administration of Novel anti-Interferon-Gamma Aptamer in severe Murine Dry Eye model (ARVO 2024) - "TXB-0063, anti-IFN-γ DNA aptamer elucidated a prominent efficacy in the dry eye model by both therapeutic and preventive administration. The efficacy of TXB-0063 observed in the severe DED model was observed in an early on-set than that of Restasis® and Xiidra®, and it also improved CD4+ T cell infiltration to the same level to the normal and goblet cell count to the normal levels. These findings suggest that this innovative TXB-0063, anti-IFN-γ aptamer has a potential to be developed to treat severe DED including Sjögren's syndrome related dry eye."

Preclinical • Corneal Abrasion • Dry Eye Disease • Ophthalmology • CD4 • IFNG

Cyclosporine Ophthalmic Solution 0.09% Improves the Signs and Symptoms of Dry Eye Disease in Patients Whose Disease Is Inadequately Controlled on Cyclosporine Ophthalmic Emulsion 0.05% (ISPOR 2024) - "Twice-daily CsA 0.09% was the preferred treatment by most patients and resulted in significant improvements in the signs and symptoms of DED at Week 12 in patients whose disease was inadequately controlled on CsA 0.05%."

Clinical • Dry Eye Disease • Inflammation • Ocular Inflammation • Ophthalmology

Early Adoption and Utilization of Perfluorohexyloctane for Treatment of Dry Eye Disease (ISPOR 2024) - " Adults (≥18 years) in the Veradigm Network Electronic Health Record (VNEHR) Database initiating DED treatment with either perfluorohexyloctane, cyclosporine ophthalmic solution 0.05% (CYC-S) (Restasis), lifitegrast (LFT) (Xiidra), and cyclosporine ophthalmic emulsion 0.09% (CYC-E) (Cequa) from September 2023 to December 2023 were selected... Early adopters of PHO were slightly younger and had a higher proportion of patients with a DED diagnosis compared to other agents. PHO tended to have more treatment-experienced patients in the 12 months prior to initiation, potentially highlighting a subgroup of the patient population who were waiting for a new treatment option for evaporative DED in addition to inflammation."

Cataract • Dry Eye Disease • Glaucoma • Inflammation • Ocular Inflammation • Ophthalmology

Efficacy of cyclosporine ophthalmic solution 0.09% in patients with dry eye disease uncontrolled on cyclosporine ophthalmic emulsion 0.05% (AMCP 2024) - No abstract available

Clinical • Dry Eye Disease • Ophthalmology

A Feasibility Study to Evaluate the Tolerability of Oph1 Compared to Restasis in Healthy Volunteers (clinicaltrials.gov) - P1 | N=20 | Completed | Sponsor: OphRx Ltd. | Not yet recruiting ➔ Completed | Trial completion date: Aug 2022 ➔ Sep 2023 | Trial primary completion date: Jul 2022 ➔ Jul 2023

Trial completion • Trial completion date • Trial primary completion date • Dry Eye Disease • Ophthalmology

A Randomized, Controlled Trial Comparing Tearcare® and Cyclosporine Ophthalmic Emulsion for the Treatment of Dry Eye Disease (SAHARA) [Response To Letter]. (PubMed, Clin Ophthalmol) - No abstract available

Journal • Dry Eye Disease • Ophthalmology

A Randomized, Controlled Trial Comparing Tearcare® and Cyclosporine Ophthalmic Emulsion for the Treatment of Dry Eye Disease (SAHARA) [Letter]. (PubMed, Clin Ophthalmol) - No abstract available

Journal • Dry Eye Disease • Ophthalmology

Rapidly Dissolving Trans-scleral Microneedles for Intraocular Delivery of Cyclosporine A. (PubMed, AAPS PharmSciTech) - "Cyclosporine A (CsA) is a cyclic peptide immunosuppressant drug that is beneficial in the treatment of various ocular diseases. Ocular distribution of CsA in a whole porcine eye perfusion model showed a significant increase of CsA levels in various posterior segment ocular tissues as compared to a topically applied ophthalmic emulsion (Restasis®) (P < 0.001). Dissolving MNs of CsA were prepared, and the MN arrays can deliver CsA to the back of the eye offering potential for treating various inflammatory diseases."

Journal • Inflammation • Ocular Inflammation • Ophthalmology

Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis (clinicaltrials.gov) - P2 | N=116 | Completed | Sponsor: SCAI Therapeutics | Active, not recruiting ➔ Completed

Trial completion • Dry Eye Disease • Ophthalmology

Treatment of ocular rosacea: a systematic review. (PubMed, J Dtsch Dermatol Ges) - "Treatment options for ocular rosacea include lid hygiene, topical and oral antibiotics, cyclosporine ophthalmic emulsion, oral vitamin A derivatives, and intense pulsed light; however, a direct comparison of treatment methods for ocular rosacea is lacking...Results suggest that topical antimicrobials, oral antibiotics, intense pulsed light. and cyclosporine were the most efficacious single modality treatments."

Journal • Review • Dermatology • Ophthalmology • Rosacea

Perfluorohexyloctane ophthalmic solution (Miebo) for dry eye disease. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Dry Eye Disease • Ophthalmology

A Randomized, Controlled Trial Comparing Tearcare and Cyclosporine Ophthalmic Emulsion for the Treatment of Dry Eye Disease (SAHARA). (PubMed, Clin Ophthalmol) - "TC provides statistically superior and sustained improvement in TBUT and multiple measures of meibomian gland secretion, and non-inferior improvement in OSDI, corneal and conjunctival staining, SANDE, EDS, and STS versus CsA. TC should be a preferred treatment for DED associated with MGD."

Clinical • Dry Eye Disease • Ophthalmology

Inside the Clinic: A Team-Based Approach to Management of GVHD : Episode 13 Frontline Treatment of Chronic GVHD (OncLive) - "Mahasweta Gooptu, MD: In the frontline setting, as it turns out, the frontline go-to regimen would still be corticosteroids for acute for as for chronic GVHD. We tend to give lower doses of steroids in chronic GVHD...Moving the drugs we used to [use] in the steroid refractory setting up to the front line is definitely one of the goals for the next decade. But for now, the frontline systemic therapy is still corticosteroids."

Video

Inside the Clinic: A Team-Based Approach to Management of GVHD : Episode 13 Frontline Treatment of Chronic GVHD (OncLive) - "Mahasweta Gooptu, MD: In the frontline setting, as it turns out, the frontline go-to regimen would still be corticosteroids for acute for as for chronic GVHD. We tend to give lower doses of steroids in chronic GVHD. You perhaps don't need such a high dose, and you will likely have to continue the therapy for a longer period. Keeping that in mind, I usually start at the lowest they can possibly get away with for frontline treatment. There are, however, effective topical therapies that we can use. For the eyes, things like Restasis [cyclosporine] or steroid eye drops; our ophthalmology colleagues have a slew of other interventions that they use which are very effective. For oral chronic GVHD, steroid rinses are extremely effective, sometimes far more effective, actually, than systemic therapy...Moving the drugs we used to [use] in the steroid refractory setting up to the front line is definitely one of the goals for the next decade. But for now, the frontline systemic..."

Video

Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis. (PubMed, BMC Ophthalmol) - "Patients receiving OTX-101 remained on treatment significantly longer and were significantly less likely to discontinue treatment than patients on CsA. Older patients remained on OTX-101 significantly longer than CsA. These findings highlight treatment pattern differences in patients with DED receiving these anti-inflammatory agents."

HEOR • Journal • Real-world • Real-world evidence • Retrospective data • Conjunctivitis • Dry Eye Disease • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Sjogren's Syndrome